Carl W. Richey

Articles

James E. Seely, PhD;Carl W. Richey;Scott D. Buckel, Ph.D;Pat D. Green

March 1st 2005

There are challenges aplenty in purification and analysis of PEGylated protein pharmaceuticals. Here are a variety of technical solutions, many concentrating on the chemistry of the linker.

Latest Updated Articles

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Published: September 11th 2024 | Updated: September 18th 2024

CPHI Pharma Award Finalists Announced for 2024

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Published: March 27th 2024 | Updated: June 28th 2024

AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product

Published: October 28th 2024 | Updated: November 22nd 2024

Discovery to Commercialization: The Right Partnerships are Key to Streamlined Drug Development

Published: November 15th 2024 | Updated: November 22nd 2024

Solving Challenges with AAV Aggregate Analysis Using a Novel Size Exclusion Particle to Determine CQAs

Published: October 28th 2024 | Updated: November 22nd 2024

Cell-based phenotypic screening with Incucyte® Live-Cell Analysis Systems

Published: October 22nd 2024 | Updated: November 22nd 2024

Optimizing cGMP Facility Design Space with a Hybrid Approach

About Us

Advertise

Editorial Information

Do Not Sell My Personal Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777